Teucrium Corn Fund vs Stryker Corporation — how do they compare? Teucrium Corn Fund trades at $18.42 (market cap $125.39M), while Stryker Corporation trades at $277.34 (market cap $106.24B). The key difference: Stryker Corporation is far larger — about 847.3× Teucrium Corn Fund's market cap, and Stryker Corporation pays a 1.27% dividend while Teucrium Corn Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Teucrium Corn Fund for 27 Days and Stryker Corporation for 21 Days on average.
| CORN | SYK | |
|---|---|---|
Market Cap | $125.39M | $106.24B |
Volume | 271,634 | 2,982,001 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $20.29 | $388.35 |
52-Week Low | $16.46 | $269.75 |
Typical Hold Time | 27 Days | 21 Days |
Enterprise Value | — | $117.70B |
Dividend Yield | — | 1.27% |
Signals from Pluang's Aura AI — not financial advice
CORN (Teucrium Corn Fund) is trading at $18.42, down 3.31% with bearish technical indicators showing 13 sell signals versus 7 buy signals. The fund recently demonstrated strong performance with a 9.7% return in July 2026, outperforming broader markets. Current technical analysis indicates oversold conditions with RSI at 29.02, while moving averages remain bearish. Agricultural commodities face mixed sentiment amid ongoing inflation concerns and geopolitical tensions affecting global supply chains.
The outlook for CORN reflects commodity market volatility with potential upside from agricultural sector strength but significant downside risk from macroeconomic pressures. Investment opportunity exists in agricultural commodity exposure, though risks include inflation trajectory, Federal Reserve policy, and geopolitical conflicts that could disrupt global corn markets and fund performance.
Stryker (SYK) trades at $277.33, up 0.7% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bearish technical signal with key support at $274 and resistance at $279, while fundamentals remain solid with a 14.43% net income margin and strong analyst consensus. Recent news highlights ongoing legal scrutiny related to a manufacturing issue disclosed in September 2026, which caused an 8.8% stock drop, but the company continues to innovate with product launches like Prophecy surgical planning.
The outlook for SYK is cautiously optimistic, with a consensus price target of $368.11 implying significant upside. Investment opportunities include robust profitability and growth in medical technology, but risks persist from legal investigations and potential operational disruptions. Investors should weigh strong analyst support against near-term sentiment headwinds.
Trailing returns across standard periods
Latest headlines on both assets
CORN is a commodity ETF that provides exposure to the price of corn futures. It uses a laddered investment strategy across multiple benchmark contracts to help minimize the impact of contango and roll costs in the agricultural market.
Read more on CORN →Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →